ArticleThe American journal of pathology2003
Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung.
Article in The American journal of pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 127 citations in OpenAlex.
- Double trouble: how co- and superinfections shape viral dynamics and host responses.Journal of virology · 2026Review
- Immune responses underpinning acute co-infections with unrelated viruses: timing and location matter.International immunology · 2025Review
- Pre-existing T Cell Memory to Novel Pathogens.ImmunoHorizons · 2023Review
- Respiratory Syncytial Virus Protects Bystander Cells against Influenza A Virus Infection by Triggering Secretion of Type I and Type III Interferons.Journal of virology · 2022Article
- Respiratory Syncytial Virus Provides Protection against a Subsequent Influenza A Virus Infection.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Infectious Bronchitis Virus (Gammacoronavirus) in Poultry Farming: Vaccination, Immune Response and Measures for Mitigation.Veterinary sciences · 2021Review
- Protective heterologous T cell immunity in COVID-19 induced by the trivalent MMR and Tdap vaccine antigens.Med (New York, N.Y.) · 2021Article
- SARS-CoV-2: is there neuroinvasion?Fluids and barriers of the CNS · 2021Review
- Type 1 innate lymphoid cells: Soldiers at the front line of immunity.Biomedical journal · 2021Review
- Longitudinal Analysis of Dengue Virus-Specific Memory T Cell Responses and Their Association With Clinical Outcome in Subsequent DENV Infection.Frontiers in immunology · 2021Article
- Effects of Asthma and Human Rhinovirus A16 on the Expression of SARS-CoV-2 Entry Factors in Human Airway Epithelium.American journal of respiratory cell and molecular biology · 2020Article
- Tissue-resident memory T cell reactivation by diverse antigen-presenting cells imparts distinct functional responses.The Journal of experimental medicine · 2020Article
- Distinct Chronic Post-Viral Lung Diseases upon Infection with Influenza or Parainfluenza Viruses Differentially Impact Superinfection Outcome.The American journal of pathology · 2020Article
- Article
- TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection.Nature · 2019Article
- Mouse Models Reveal Role of T-Cytotoxic and T-Reg Cells in Immune Response to Influenza: Implications for Vaccine Design.Viruses · 2019Review
- The effect of respiratory viruses on immunogenicity and protection induced by a candidate universal influenza vaccine in mice.PloS one · 2019Article
- Attenuation of Influenza A Virus Disease Severity by Viral Coinfection in a Mouse Model.Journal of virology · 2018Article
- Virological and Immunological Outcomes of Coinfections.Clinical microbiology reviews · 2018Review
- Investigating Viral Interference Between Influenza A Virus and Human Respiratory Syncytial Virus in a Ferret Model of Infection.The Journal of infectious diseases · 2018Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Having previously shown that previous immunity to one virus can influence the host response to a subsequent unrelated virus, we questioned whether the outcome to a given virus infection would be altered in similar or different ways by previous immunity to different viruses, and whether immunity to a given virus would have similar effects on all subsequent infections. In mouse models of respiratory viral infections, immunity to lymphocytic choriomeningitis virus (LCMV), murine cytomegalovirus (MCMV), or influenza A virus enhanced both Th1-type cytokine responses and viral clearance in the lung on vaccinia virus infection. A common pathological feature was the presence of chronic mononuclear infiltrates instead of the acute polymorphonuclear response seen in the infected nonimmune mice, but some pathologies such as enhanced bronchus-associated lymphoid tissue and bronchiolitis obliterans were unique for the immunizing virus, LCMV. Immunity to influenza virus influenced subsequent infections diversely, inhibiting vaccinia virus but enhancing LCMV and MCMV titers and completely altering cytokine profiles. Influenza virus immunity enhanced the mild mononuclear responses usually observed during acute infections with MCMV or LCMV in nonimmune mice, but unique features such as enhanced bronchiolization and mononuclear consolidation occurred during MCMV infection of influenza virus-immune mice. Heterologous immunity induced two patterns of disease outcome dependent on the specific virus infection sequence: improved, if the acute response switched from a neutrophilic to a lymphocytic response or worsened, if it switched from a mild to a severe lymphocytic response. Heterologous immunity thus occurs between many viruses, resulting in altered protective immunity and lung immunopathology, and this is influenced by the specific virus infection sequence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.